Electrospun Antimicrobial, Anti-Inflammatory and Analgesic Bandages for Comprehensive Wound Treatment
Conference Paper
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
Chronic wounds affect more than 5 million Americans annually with an associated cost of $10 20 billion. These wounds provide perfect environments for bacterial growth, and are prone to infections, especially from multidrug resistant (MDR) pathogens. The current silverbased bandages used to treat wounds exhibit a high toxicity toward fibroblasts, and lack antiinflammatory and analgesic activity. Our work focuses on the development of bandages to address these unmet clinical needs. We have fabricated electrospun polycaprolactone (PCL) scaffolds, capable of aiding in the wound healing process, and with incorporation of Ag+IBU, a novel therapeutic. These scaffolds deliver the drug locally at a controlled rate to impede bacterial infections. We have further functionalized PCL scaffolds with addition of polyethylene glycol (PEG) to accelerate drug release. Scanning electron microscopy images have revealed that our drug loaded scaffolds have a smooth fiber morphology and fiber diameter that is ~1 m. Scaffolds loaded with either 5% or 10% Ag+IBU (w/w) release 40% of the drug within the first 24 hours. Microbiological assays have revealed that Ag+IBUloaded scaffolds are bactericidal against bacteria in both planktonic and biofilm growth mode. Cytotoxicity assays have revealed that Ag+IBUloaded scaffolds exhibit toxicity toward human dermal fibroblasts at high concentrations. However, preincubation with Nacetyl cysteine (NAC), an antioxidant metabolite, abrogates this toxicity and significantly increases cell viability. We have fabricated twolayer scaffolds with one layer rapidly delivering NAC and the second layer slowly releasing Ag+IBU. Compared with the commercially available bandages with antimicrobial properties currently used for wounds, our nontoxic, antimicrobial, antiinflammatory, and analgesic scaffolds offer a more comprehensive treatment option.Support or Funding InformationThis research is supported by NIH grant 5R21AI14232702
